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CASE REPORT
Metastatic meningioma: positron emission tomography CT
imaging findings
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and 1M M MAHER
1Department of Radiology, Cork University Hospital and University College Cork, Cork, Ireland, 2Neuroscience Divisions,
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ABSTRACT. The imaging findings of a case of metastasing meningioma are described.
The case illustrates a number of rare and interesting features. The patient presented
with haemoptysis 22 years after the initial resection of an intracranial meningioma. CT
demonstrated heterogeneous masses with avid peripheral enhancement without
central enhancement. Blood supply to the larger lesion was partially from small feeding
vessels from the inferior pulmonary vein. These findings correlate with a previously
published case in which there was avid uptake of fluoro-18-deoxyglucose peripherally
with lesser uptake centrally. The diagnosis of metastasing meningioma was confirmed
on percutaneous lung tissue biopsy.
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Typically, meningiomas are slow-growing benign
neoplasms of the central nervous system derived from
meningothelial cells; these neoplasms account for about
25% of intracranial tumours [1]. Meningiomas are graded
from I to III indicating increasing grades of malignancy
according to World Health Organization (WHO) criteria
[1]. Meningiomas are usually indolent, slow-growing
tumours and surgery is curative in the majority of cases
[2, 3]. We present a rare case of a woman who had
resection of an intracranial meningioma performed 22
years previously. The patient presented with haemop-
tysis and on imaging was found to have bilateral
pulmonary lesions; these were confirmed as metastatic
meningioma following CT-guided percutaneous biopsy.
This report focuses primarily on the imaging features of
a meningioma that metastasised to lung. Particular
reference is given to CT and combined positron emission
tomography and CT (PET/CT) appearances. The role of
percutaneous lung biopsy in histological confirmation of
the diagnosis is also briefly discussed.
Case report
A 74-year-old woman presented with haemoptysis.
She had a history of intracranial meningioma, resected
22 years previously in 1985. The patient had undergone
two further resections for intracranial local recurrence
in 1988 and 1992 (3 years and 7 years following initial
resection, respectively). A chest radiograph revealed
two well-circumscribed masses, one at each lung base
without a pleural abnormality. CT scan of the thorax
was performed and included unenhanced, arterial phase
(25 s post-iv contrast administration) and portal venous-
phase (75 s post-iv contrast administration) imaging
(Figure 1). CT demonstrated two well-circumscribed
rounded lesions, which were peripherally located in
the lungs: a 3.8 cm mass in the right lower lobe and a
second 2.7 cm mass in the left lower lobe. The lesions
had low-density centres (21 HU) that did not signifi-
cantly enhance post-iv contrast administration (29 HU
in arterial and portal venous phase images). The peri-
phery of the lesions enhanced from 50 HU on the unen-
hanced images to 111 HU on the arterial phase images
and de-enhanced to 83 HU on portal venous-phase
images. The periphery of these lesions, therefore, en-
hanced avidly post-iv contrast administration; the lesions
were noted to have prominent feeding vessels in their
walls, which were fed by branches of the inferior
pulmonary veins. CT scan of the brain (pre and post iv
contrast administration) showed no evidence of recur-
rent or metastatic disease.
Full-body combined fluoro-18-deoxyglucose (FDG)
PET/CT imaging demonstrated avid FDG uptake within
both lung lesions with standard uptake values (SUV) of
8.7 on the right and 7.1 on the left (Figure 2). There was
slightly less FDG uptake in the centre of each lesion.
There was no other focal area of uptake of FDG to
suggest metastatic disease elsewhere.
The patient was referred for CT-guided percutaneous
lung biopsy. Under fluoroscopic CT guidance, a 10-cm
19/20-gauge coaxial core biopsy needle system (Temno;
Cardical Healthcare, Dublin, OH) was advanced into the
larger of the two lesions located in the right lower lobe.
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Figure 1. CT in (a) the control, (b) arterial and (c) portal venous phases post-iv contrast administration. There is a 3.8-cm well-
circumscribed rounded lesion in the right lower lobe (arrow). Decreased attenuation is seen in the centre of the lesion. The
lesion has a prominent feeding vessel in the wall (arrowhead), which was fed by a branch of the right inferior pulmonary vein.
(a) (b)
Figure 2. (a, b) Full-body combined fluoro-18-deoxyglucose positron emission tomography (FDG-PET)/CT imaging demonstrated
avid uptake of FDG within both lung lesions; standard uptake values were 8.7 on the right and 7.1 on the left. There was slightly
decreased FDG uptake in the centre of the lesions.
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Four cores of tissue were obtained. During the biopsy,
the operators noted that the lesions were very vascular;
however, there were no post-procedure complications.
Histological examination demonstrated multiple foci of
tumour within lung parenchyma, identical in appearance
to the original intracranial meningioma. The original
meningioma was parasagittal and all three intracranial
specimens showed areas of necrosis indicating increased
risk of recurrence (atypical meningioma WHO Grade II).
The recurrent tumour in 1998 showed tumour invasion
of the sagittal sinus. Both the original and metastatic
tumour cells stained positive with antigens to both
epithelial membrane antigen and vimentin, typical of
meningiomas, on immunocytochemistry. Both the intra-
cranial and metastatic tumour showed areas of central
tumour necrosis. Repeat cranial imaging did not show
any residual or recurrent neoplasm. The patient was
reviewed by a cardiothoracic surgeon, who recom-
mended surgical resection. The patient declined surgical
intervention. On clinical follow-up 10 months following
diagnosis of the pulmonary lesions, the patient was
asymptomatic and had noted no further episodes of
haemoptysis.
Discussion
The majority of meningiomas are benign tumours of
the central nervous system and arise from the leptome-
ninges [1, 3]. They account for approximately 25% of all
intracranial tumours [1, 3]. Grade I meningiomas are
regarded as benign, because of their slow growth and
rare tendency to recur locally or metastasise [3, 4]. Grade
II meningiomas, as reported in this case, have an
increased risk of recurrence. The 5 year recurrence rate
for meningiomas with benign histological features is
approximately 3% [5]. Consequently, surgery is the
treatment of choice and the only definitive cure [6].
Distant extracranial metastases from primary intracra-
nial meningiomas have been previously described but
are rare; the incidence of metastasis is less than 1 in 1000.
Although primary meningiomas are 2–4 times more
likely to occur in females, the male to female ratio of
metastatic disease is 3:2 [7]. The reported age range for
metastases is 1 week to 83 years, although 75% of cases
are found in patients between 40 and 60 years of age [7].
A previous series reported the time from initial diagnosis
to discovery of metastases to be approximately 5 years.
Some 60% of extracranial metastases from meningioma
are found in the lung, while the liver, lymph nodes and
bone are less common sites [4, 8–11]. Haematogenous
spread of tumour cells as a result of venous sinus
invasion is the most likely mechanism of metastasis [12].
A second route of dissemination is through the cere-
brospinal fluid, leading to tumour of the neuraxis [7].
Irrespective of the route of dissemination, 75% of pa-
tients with metastatic meningioma will have had previous
surgery on the primary lesion [7]. As discussed above,
venous sinus invasion is themost plausible explanation for
the development of metastases. Parasagittal meningiomas
have a higher rate of metastasis [6]. In our patient, the
original intracranial meningioma was parasagittal and
vascular invasion of the sagittal sinus was reported in the
recurrent tumour removed in 1988. The most unusual
feature of our patient’s presentation was the length of time
to discovery of distant metastases. In our view, as invasion
of the sagittal sinus was present in 1988 and there was no
further evidence of intracranial disease since 1992, it is
likely that pulmonary metastases were present for at least
15 years. The discovery of metastatic meningioma more
than 20 years from initial diagnosis is extremely rare. The
mean duration from initial diagnosis to development of
metastases is 6 years, although there is one report from
Japan of pulmonary metastatic meningioma 26 years post
craniotomy [13, 14].
The imaging features of the metastases in this case are
interesting. Firstly, there were only two nodules detect-
able on imaging. This is consistent with previous reports,
which indicated that pulmonary metastases number more
than three in only 13% of cases [15]. Rapid enhancement
of pulmonary lesions post iv contrast, as seen in the
present case, is similar to that of intracranial meningio-
mas. In this case, lesions were of lower attenuation
centrally with poor central enhancement. A previous
report by Yekeler et al [6] described the MRI features of
pulmonary metastatic meningioma and reported higher
signal intensity centrally on T2 weighted sequences,
suggesting a central ‘‘cystic’’ component. The central
‘‘cystic’’ component for metastatic meningioma to lung
had not been previously reported, but had been described
with selected intracranial meningiomas [6]. In the current
case, it is likely that the central low-density areas within
both lesions seen on CT would show relative increased
signal intensity on T2 weighted images when compared
with the periphery, as described in the case report by
Yekeler et al [6], especially in view of the central necrosis
on histology.
There are few examples of the use of PET in the initial
characterisation and surveillance of meningiomas. In
2007, Rutten et al [16] described the combination of CT
and MRI as limited in the diagnosis of local skull
involvement from adjacent intracranial meningioma. In
their study, the authors demonstrated that skull-base
tumours could be clearly visualised with 18F-tyrosine
PET, even after radiation therapy [16, 17]. Primary
intracranial meningioma is typically reported as hav-
ing low FDG uptake, because glucose metabolism in
meningioma is similar to that of surrounding tissue [15].
There have been a few isolated reports describing the
imaging features of metastatic meningioma on FDG-PET
imaging. Ghodsian et al [18] described a moderately
hypermetabolic sacral metastatic mass by FDG-PET/CT.
This was a Grade III malignant meningioma on his-
tology. Meirelles et al [19] recently described a pulmon-
ary meningioma that manifested as a solitary pulmonary
nodule and had very high metabolic activity on PET
scan. The current case also showed avid uptake of FDG;
the SUV was .7 in each pulmonary lesion. The uptake
was more avid in the periphery and slightly less in the
centre of both lesions, corresponding to the central areas
of low density on CT. It was useful to note that there
were no other foci of abnormal FDG uptake elsewhere to
suggest other metastases. It is reassuring to note that
10 months after the PET/CT with clinical follow-up, the
patient remains asymptomatic with no evidence of
local or distant spread. The diagnosis of pulmonary
metastatic meningioma was confirmed histologically
by CT-guided percutaneous biopsy, which has been
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previously reported [20]. This diagnosis enabled the
cardiothoracic surgeon to discuss treatment options with
the patient, confident that he was dealing with metastatic
meningioma. In this case the patient declined surgical
resection and remains asymptomatic.
Conclusion
Metastatic meningioma is a rare cause of pulmonary
mass. The present case demonstrates one such case in
which the metastatic lesions have decreased attenuation
centrally with higher attenuation peripherally and avid
peripheral enhancement following intravenous contrast
administration on CT. A feeding vessel was identified on
CT and on FDG-PET both lesions were found to be FDG-
avid, particularly peripherally.
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